Revolution Medicines Receives FDA Approval for Rasonque; Analysts Forecast $11.5 Billion Peak Sales
Revolution Medicines (NASDAQ:RVMD) received full FDA approval in just one month after submitting its drug daraxonrasib, now branded as Rasonque, to treat metastatic pancreatic cancer. The rapid regulatory clearance is attributed to the Commissioner's National Priority Voucher program, which accelerates approvals for high-potential therapies targeting difficult-to-treat diseases like pancreatic cancer. Rasonque works by inhibiting multiple forms of the RAS protein using a novel molecular glue mechanism and demonstrated strong results in Phase 3 trials. The drug is well tolerated compared to traditional chemotherapy and has generated significant investor interest, contributing to Revolution's stock surging over 178% year-to-date. Analysts at RBC Capital Markets project $28 million in sales for the current quarter with a potential peak of $11.5 billion annually worldwide. The European Medicines Agency is also reviewing the drug under an accelerated process, suggesting strong international market prospects.
Topics: biotech drug approval pharmaceuticals stock valuation